Repeated Swim Impairs Serotonin Clearance Via a Corticosterone-sensitive Mechanism: Organic Cation Transporter 3, the Smoking Gun
Overview
Affiliations
Activation of the hypothalamic-pituitary-adrenal (HPA) axis is associated with increased extracellular serotonin (5-HT) in limbic brain regions. The mechanism through which this occurs remains unclear. One way could be via HPA axis-dependent impairment of serotonin transporter (SERT) function, the high-affinity uptake mechanism for 5-HT. Consistent with this idea, we found that 5-HT clearance rate in hippocampus was dramatically reduced in mice exposed to repeated swim, a stimulus known to activate the HPA axis. However, this phenomenon also occurred in mice lacking SERT, ruling out SERT as a mechanism. The organic cation transporter 3 (OCT3) is emerging as an important regulator of brain 5-HT. Moreover, corticosterone, which is released upon HPA axis activation, blocks 5-HT uptake by OCT3. Repeated swim produced a persistent elevation in plasma corticosterone, and, consistent with prolonged blockade by corticosterone, we found that OCT3 expression and function were reduced in these mice. Importantly, this effect of repeated swim to reduce 5-HT clearance rate was corticosterone dependent, as evidenced by its absence in adrenalectomized mice, in which plasma corticosterone levels were essentially undetectable. Behaviorally, mice subjected to repeated swim spent less time immobile in the tail suspension test than control mice, but responded similarly to SERT- and norepinephrine transporter-selective antidepressants. Together, these results show that reduced 5-HT clearance following HPA axis activation is likely mediated, at least in part, by the corticosterone-sensitive OCT3, and that drugs developed to selectively target OCT3 (unlike corticosterone) may be candidates for the development of novel antidepressant medications.
Organic cation transporters in psychiatric and substance use disorders.
Honan L, Fraser-Spears R, Daws L Pharmacol Ther. 2023; 253:108574.
PMID: 38072333 PMC: 11052553. DOI: 10.1016/j.pharmthera.2023.108574.
Clauss N, Mayer F, Owens W, Vitela M, Clarke K, Bowman M Mol Psychiatry. 2023; 28(7):2934-2945.
PMID: 37308680 PMC: 10615754. DOI: 10.1038/s41380-023-02064-5.
Scholl J, Solanki R, Watt M, Renner K, Forster G Brain Res. 2022; 1800:148189.
PMID: 36462646 PMC: 9837808. DOI: 10.1016/j.brainres.2022.148189.
Andrews P, Bosyj C, Brenton L, Green L, Gasser P, Lowry C Proc Biol Sci. 2022; 289(1986):20221565.
PMID: 36321487 PMC: 9627707. DOI: 10.1098/rspb.2022.1565.
Organic Cation Transporters in Psychiatric Disorders.
Daws L Handb Exp Pharmacol. 2021; 266:215-239.
PMID: 34282486 PMC: 9281871. DOI: 10.1007/164_2021_473.